TNF and Cowden disease: This has been observed in the case of anti‐TNF‐α mAbs like IFX and adamuzumab, which have shown the ability to induce complete mucosal healing in CD patients, whereas the anti‐TNF F(ab)2 fragment (cetuzumab) has exhibited a limited efficacy.54